Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.40 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.35 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.35 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14439104 | 0.82 | ITGB2 (0.50) | MAPK1KDM4EALDH1A1LMNAHTR1A | |
| SCHEMBL20780774 | 0.78 | ITGB2 (0.41) | MAOBKDM4ELMNAITGB2ICAM1 | |
| SCHEMBL7594061 | 0.76 | ABCG2 (0.55) | ABCG2GSK3BTTBK1TTBK2PKM | |
| SCHEMBL12531168 | 0.75 | ABCG2 (0.36) | ABCG2 | |
| SCHEMBL30521296 | 0.74 | ABCG2 (0.52) | ABCG2GSK3BTTBK1TTBK2PKM | |
| SCHEMBL1224045 | 0.74 | ABCG2 (0.52) | ABCG2GSK3BTTBK1TTBK2PKM | |
| SCHEMBL25477727 | 0.74 | EED (0.46) | ABCG2GSK3BPKMTSHREED | |
| SCHEMBL1145518 | 0.74 | EED (0.46) | ABCG2GSK3BPKMTSHREED | |
| SCHEMBL1145960 | 0.73 | ABCG2 (0.50) | ABCG2GSK3BTTBK1TTBK2PKM | |
| SCHEMBL352307 | 0.73 | ABCG2 (0.50) | ABCG2GSK3BTTBK1TTBK2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4710923-A2 | INDOLE AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3612030-B1 | INDOLE AHR INHIBITORS AND USES THEREOF | IKENA ONCOLOGY INC (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025129168-A1 | TRIAZOLONE INHIBITORS OF NICOTINAMIDE N-METHYLTRANSFERASE AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-114746408-B | Alkynyl- (heteroaryl) -carboxamide HCN1 inhibitors | 豪夫迈·罗氏有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2024-09-03 | — | — | US | disclosed |
| CN-110831600-B | Indole AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ONCOLYS BIOPHARMA, INC. (JP) | 2023-06-22 | — | — | US | disclosed |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| EP-2532652-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | Kagoshima University (JP) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011093483-A1 | THERAPEUTIC AGENT FOR HEPATITIS C | 国立大学法人鹿児島大学 (JP) | 2011-08-04 | — | — | WO | disclosed |
| US-RE36256-E | ADMINISTERING ARYL-SUBSTITUTED QUINOXALINE DERIVATIVES AS ANTIPROLIFERATIVE, ANTICARCINOGENIC AND ANTITUMOR AGENTS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1999-07-20 | — | — | US | disclosed |
| US-5795889-A | INHIBITING CELL GROWTH WITH ENZYME INHIBITORS FOR SKIN DISORDERS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0584222-B1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE POULENC RORER INT (US) | 1997-10-08 | — | — | EP | disclosed |
| US-5656643-A | QUINOLIN PYRIDINE DERIVATIVES; USEFUL FOR TREATING CANCER, LEKEMIA, PSORIASIS, INFLAMMATORY DISODERS, BONE DISORDERS, ATHEROSCLEROSIS AND RESTENOSIS; CONTROLLS CELLULAR REPRODUCTION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-08-12 | — | — | US | disclosed |
| US-5646153-A | INHIBITING ABNORMAL CELL PROLIFERATION | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5480883-A | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-01-02 | — | — | US | disclosed |
| US-5409930-A | Inhibits abnoramal cell proliferation; dimethoxyquinoline/ dimethylquinoline/ quinolineoxide/ and quinoxaline derivatives | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1995-04-25 | — | — | US | disclosed |
| WO-1992020642-A1 | BIS MONO-AND BICYCLIC ARYL AND HETEROARYL COMPOUNDS WHICH INHIBIT EGF AND/OR PDGF RECEPTOR TYROSINE KINASE | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528784-B2 | Alkynyl-(heteroaryl)-carboxamide HCN1 inhibitors | HCN1, HCN2, HCN3 | ABCG2 236/4885GSK3B 1530/4885TTBK1 2518/4885 |
| US-20230192622-A1 | ANTI-SARS-COV-2 DRUG | ACE2, ACE, SARS1 | ABCG2 189/4885GSK3B 4176/4885TTBK1 4369/4885 |
| US-20250122205-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ABCG2 160/4885GSK3B 489/4885TTBK1 3062/4885 |
| US-20230028336-A1 | INDOLE AHR INHIBITORS AND USES THEREOF | AHR, ARNT, IDO1 | ABCG2 160/4885GSK3B 489/4885TTBK1 3062/4885 |
| US-12077542-B2 | Indole AHR inhibitors and uses thereof | AHR, ARNT, IDO1 | ABCG2 160/4885GSK3B 489/4885TTBK1 3062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.